Tedalinab

• UNSPSC Description:

  Tedalinab (GRC-10693) is a potent, orally active, and selective cannabinoid receptor 2 (CB2) agonist. Tedalinab has >4700-fold functional selectivity for CB2 over CB1. Tedalinab has potential for neuropathic pain and osteoarthritis treatment[1].

• Target Antigen:

  Cannabinoid Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/tedalinab.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=C(C1=NN(C2=CC=C(F)C=C2F)C3=C1[C@@]4([H])CC[C@]3([H])C4)NC(C)(C)C

• Molecular Weight:

  345.39

• References & Citations:

  [1]Glenmark’s molecule for neuropathic pain, osteoarthritis - GRC 10693, successfully completes Phase I trials.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  Phase 1

• CAS Number:

  916591-01-0